White Paper

Role Of Cell Based Potency Assay In Functional Characterization Of Therapeutic Monoclonal Antibodies (mAbs)

Source: MilliporeSigma

By Agata Burzawa and Pamela Hamill, Ph.D.

Lab

Characterization of an originator monoclonal antibody (mAb), or comparability study between originator mAb and biosimilar candidate mAb, are challenging due to the highly complex and variable structure of monoclonal antibodies. The heterogeneity that can arise in quality attributes, including structural alterations, oxidation, deamination or glycosylation, can impact the potency and the efficacy of the final product. Moreover, mAbs have multiple biological functions associated with both the specific antigen binding (Fab) region and interaction with C1q and Fc receptors via the Fc region of the antibody. For this reason, the characterization of therapeutic monoclonal antibodies should include a wide range of analytical techniques; as well as binding and cell-based potency assays in order to reflect the main mechanism of action and effector function of the mAb of interest.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: